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Clinical significance points 
1. There is little data comparing Non-ST Elevation Acute Coronary Syndrome vs ST Elevation 
Myocardial Infarction elderly patients treated by percutaneous coronary intervention.  
2. Despite more favorable baseline characteristics, elderly patients with ST Elevation 
Myocardial Infarction treated by percutaneous coronary intervention have twice the risk of 
one-year mortality and stroke compared to Non-ST Elevation Acute Coronary Syndrome 
patients.   
3. These findings may be important for tailoring follow-up strategies. 
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ABSTRACT 
Introduction: Acute coronary syndromes have been classified according to the finding of ST-
segment elevation on the presenting ECG, with different treatment strategies and practice 
guidelines. However, a comparative description of the clinical characteristics and outcomes of acute 
coronary syndrome elderly patients undergoing percutaneous coronary intervention during index 
admission has not been published so far.    
Methods: Retrospective cohort study of patients enrolled in the Elderly-ACS 2 multicenter 
randomized trial. Main outcome measures were crude cumulative incidence and cause-specific 
hazard ratio (cHR) of cardiovascular death, non-cardiovascular death, reinfarction and stroke. 
Results: Of 1443 ACS patients aged >75 years (median age 80, IQR 77-84), 41% were classified as 
ST Elevation Myocardial Infarction (STEMI), and 59% had Non-ST Elevation ACS (NSTEACS) 
(48% NSTEMI and 11% unstable angina). As compared to those with NSTEACS, STEMI patients 
had more favorable baseline risk factors, less prior cardiovascular events and less severe coronary 
disease, but lower ejection fraction (45% vs 50%, p<0.001). At a median follow up of 12 months, 
51 (8.6%) STEMI patients had died, versus 39 (4.6%) NSTEACS patients. After adjusting for sex, 
age and previous myocardial infarction, the hazard among the STEMI group was significantly 
higher for cardiovascular death (cHR- 1.85; 95% CI 1.02-3.36), non-cardiovascular death (cHR 
2.10; 95% CI 1.01-4.38), and stroke (cHR 4.8; 95% CI 1.7-13.7).  
Conclusions:  Despite more favorable baseline characteristics, elderly STEMI patients have worse 
survival and a higher risk of stroke compared to NSTEACS patients after percutaneous coronary 
intervention. 
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The clinical spectrum of acute coronary syndrome (ACS) has been classified according to the 
presenting ECG into ST-Elevation Myocardial Infarction (STEMI) and Non-ST Elevation ACS 
(NSTEACS). As testified by the fact that separate Practice Guidelines exist for the two clinical 
conditions,1-4 this subdivision has important pathophysiological and, more importantly, therapeutic 
implications, since immediate reperfusion therapy is recommended in STEMI [either using 
fibrinolytic therapy or primary percutaneous coronary intervention]1,2, whereas NSTEACS 
mandates early risk stratification and a more graded invasive approach3,4. Patients with NSTEACS 
have been shown to be older than STEMI patients, with worse baseline characteristics and to have 
worse long-term outcomes.5 Part of this unfavorable outlook may also depend on the fact that only 
about two-thirds of NSTEACS patients are suitable for revascularization, as compared to the almost 
totality of STEMI patients. However, it is uncertain whether the differences in clinical 
characteristics and outcome persist in the elderly patients with ACS. 
In the present study, we investigated the clinical and coronary angiographic characteristics of 
patients aged >75 years with either STEMI or NSTEACS treated by percutaneous coronary 
intervention in the Elderly ACS 2 randomized trial6 and followed-up them for 12 months to 
compare their major cardiovascular outcomes.       
 
METHODS 
Patient Population 
The Elderly ACS 2 trial6 was a randomized, multicenter study carried out at 32 centers in Italy, 
comparing reduced-dose prasugrel (5 mg once daily) and standard-dose clopidogrel (75 mg once 
daily) in patients aged >75 years undergoing percutaneous coronary intervention. The trial was 
designed as event-driven and enrolment had to continue until at least 492 primary adjudicated 
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events had occurred in the combined treatment groups. The trial started in November 2012 and was 
interrupted on January 25, 2017 due to futility for efficacy after the results of a planned interim 
analysis of the first 1000 patients with completed 12-month follow-up. Overall, 1443 patients were 
enrolled across the ACS spectrum including STEMI and NSTEACS.  
Outcomes 
The original endpoint of the Elderly ACS 2 study was a composite of all-cause mortality, 
myocardial (re)infarction, disabling stroke and re-hospitalization for cardiovascular causes or 
bleeding, within one year.6 For the present study, we considered cardiovascular mortality and in 
addition non-cardiovascular mortality, re-infarction and overall stroke. All the study characteristics, 
inclusion and exclusion criteria, as well as endpoint definitions have been reported previously6. 
Statistical Analysis 
Continuous variables were tested for normality using the Shapiro-Wilk test and are reported as 
mean and standard deviation if normally distributed, or medians and 25th and 75th percentiles if 
they did not satisfy the normal assumption. Categorical variables are shown as frequencies and 
percentages in each ACS group. 
To describe the first signal of unfavourable outcome, the numbers and percentages of first events 
observed during the follow-up were reported in a table separately by ACS group. The data were 
provided separately for the type of first event (cardiovascular mortality, non-cardiovascular 
mortality, re-infarction, stroke) distinguishing between the events observed up to the first 30 days 
and in the whole follow-up.  
In each ACS group, the cumulative probability of observing the single type of first event (crude 
cumulative incidence function, CCI) was estimated as a function of time by the Aalen Johansen 
estimator for competing risks. This estimator was used to remove the bias due to the presence of 
right censoring from the percentages of events observed up to 30 days and in the whole follow-up. 
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The CCIs of a given type of first event were compared between ACS groups by the Gray’s test7. Of 
note, the CCI of the single type of first event is affected by the indirect protection of the competing 
events, since the more the competing event occurs as first, the lower is the proportion of patients 
that may develop the type of first event under analysis. This motivates that to evaluate the 
prognostic role of the ACS group we resorted to cause specific rates in time windows and cause 
specific hazard of each type of first event. The rate of the single type of first event was calculated in 
each ACS group splitting follow-up time in the first 30 days and from the 31st day on. The rates of a 
given type of first event were compared between ACS groups by the exponential model.   
The cause specific hazard ratio (cHRs) and corresponding 95% confidence intervals (Cis) for 
patients with STEMI versus NSTEACS were calculated by using univariate Cox regression models. 
Cox regression models were also adjusted for age (entered as the following four dummy variables: 
75-79, 80-84, 85-89, ≥90 years), gender and previous MI. Visual inspection of the Shoenfeld 
residual plot and the test proposed by Grambsch 8 were used to assess the proportional hazards 
assumption.  The analyses were performed using STATA version 14 (Stata Corp., College Station, 
TX) and R software 3.5.1, and R version 3.4.1 (2017-06-30). 
 
RESULTS 
Study population 
The distribution of patients’ baseline clinical characteristics, features of the index ACS event, 
angiographic and percutaneous coronary intervention data, and drug therapy during admission and 
at discharge, are summarized in TABLES 1-3 by ACS group (STEMI vs NSTEACS). On the 
presenting ECG, 595 (41.0%) were classified as STEMI, whereas 848 (59.0%) had NSTEACS. 
Based on cardiac troponin levels, 100% of the ST Elevation patients were classified as STEMI, 
whereas among the NSTEACS patients 694 (82%) were Non-ST Elevation myocardial infarction 
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and 154 (18%) unstable angina. Women were more frequent among STEMI patients, whereas age 
and body mass index were almost comparable. Diabetes, hypertension, hypercholesterolemia, 
chronic respiratory failure as well as previous cardiovascular events (prior myocardial infarction, 
prior percutaneous coronary intervention, prior bypass surgery and peripheral vascular disease) 
were less frequent among STEMI as compared to NSTEACS patients, whereas the prevalence of 
current smokers was comparable. Ongoing cardiovascular medications were also less frequent in 
the STEMI group.  
STEMI patients had less extensive coronary artery disease, including left main and 3-vessel disease. 
However, STEMI patients had significantly lower residual left ventricular ejection fraction. Among 
the patients treated with stenting [539 STEMI (96.4%) and 787 with NSTEACS (94.2%)], the 
proportion of patients who implanted drug eluting stents was significantly smaller in STEMI 
patients (66% vs 75% in NSTEACS, p<0.001).  
Finally, STEMI patients were more commonly treated with glycoprotein IIb/IIIa antagonists and 
bivalirudin in the periprocedural period. Medications at discharge were comparable.  
The length of hospital stay was significantly longer for STEMI patients (median 6 days, IQR 5-9 
days) compared to patients with NSTEMI (median 6, IQR 4-8 days) (p<0.01). 
One-year outcome  
The median follow-up duration was 12 months (range, 3–13 months), with 23 patients (1.5%) lost 
to follow-up. The number of observed events (as first event) in STEMI and NSTEACS patients is 
shown in TABLE 4. Among STEMI patients, a total of 44 deaths from any cause (7.4%) were 
observed. Three out of 7 patients with reinfarction and 4 out of 15 patients with stroke died within 
the end of follow up; among the 3 patients died after reinfarction, 2 died the same day when 
myocardial infarction occurred, whereas in the third death occurred 6 months after myocardial 
infarction. Among the 4 patients dead after stroke, death occurred a few days after stroke in 3 cases, 
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whereas in 1 case the patient experienced a non-disabling in-hospital stroke and died after 11 
months. 
Among NSTEACS patients, a total of 35 deaths from any cause were observed. Four patients out of 
31 with reinfarction died within the end of follow up, in 3 cases a few days after myocardial 
infarction and in 1 case 5 months later. 
Nineteen patients experienced stent thrombosis (ST), classified as definite in 5 cases [2 (0.3%) 
among STEMI and in 3 (0.3%) among NSTEACS patients] and probable in 14 [9 (1.5%) among 
STEMI and 5 (0.5%) among NSTEACS patients]. Three patients had non-fatal myocardial 
infarction, 14 had sudden cardiac death, whereas 2 patients (both with STE as presenting ECG) had 
fatal myocardial infarction (in 1 patient death occurred after 6 months and in 1 patient occurred the 
same day, 6 days after study inclusion).  Eleven patients (2.0%) among STEMI and 38 (4.5%) 
among NSTEACS patients had BARC 2-5 bleeding events (p=0.02). Only one patient with 
NSTEACS at admission experienced a fatal bleeding. 
The CCI functions for cardiovascular mortality, non-cardiovascular mortality, re-infarction and 
stroke are displayed in Figure 1.  A higher incidence of cardiovascular mortality, non- 
cardiovascular mortality and stroke was observed among STEMI patients, whereas the incidence of 
re-infarction was higher among patients with NSTEACS. The 30-day and one-year crude 
cumulative rates of study outcomes according to the presenting ECG are reported in TABLE 4. 
Results on the prognostic impact of the ACS group regarding the different types of first events are 
reported in TABLE 5. As compared to NSTEACS patients, those with STEMI had a higher rate of 
cardiovascular mortality in the first 30-day time window, a lower rate of infarction and a higher rate 
of stroke in the time window from the 31st day on. In the Cox regression model, the presence of 
STEMI was associated to higher cardiovascular (cHR 1.70; 95% CI 0.97-3.01) and non-
cardiovascular mortality (cHR 2.01; 95% CI 0.99-4.11), stroke (cHR 4.25; 1.55-11.7) and with a 
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lower risk of myocardial infarction (cHR 0.33; 95% CI 0.14-0.74). After adjusting for sex, age and 
previous MI, STEMI remained a significant and independent predictor of cardiovascular death 
(cHR 1.85; 95% CI 1.02-3.36), non-cardiovascular death (cHR 2.10; 95% CI 1.01-4.38) and stroke 
(cHR 4.80; 95% CI 1.68-13.7), whereas the association with reinfarction became nonsignificant 
(cHR 0.44, 95% CI 0.19-1.03). 
DISCUSSION 
The present study confirms that, even in older adults, STEMI and NSTEACS are two different 
clinical syndromes of acute coronary artery disease. It has long been established that, as compared 
to STEMI patients, those with NSTEACS are older and have a longer history of coronary artery 
disease, including prior MIs end revascularization procedures5. These worse characteristics persist 
at present time and are independent from the age difference between the two patient populations. 
Therefore, even in the elderly, the STEMI presentation is indicative of an abrupt closure of a major 
coronary segment in the lack of collateral circulation and myocardial preconditioning, these two 
conditions being more typical of patients with longer history of coronary artery disease and 
revascularization procedures, such as those with NSTEACS. Besides the different pathogenetic 
mechanism, and due to the lack of collateral circulation, on average the STEMI presentation is 
associated with larger myocardial damage and lower residual left ventricular function, as also 
shown in the present study.  
A further mechanism is the possible protective effect of several cardiovascular medications more 
frequently in use among NSTEACS patients at the time of admission. Some of these medications 
(aspirin and clopidogrel) may have prevented complete coronary occlusion, whereas others (statins, 
betablockers and ACE-inhibitors) may have reduced plaque instability and myocardial oxygen 
requirement. 
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A surprising and new finding of the present study is the 50% higher risk of cardiovascular and non-
cardiovascular death at 12 months observed among STEMI patients, as compared to those with 
NSTEACS. This finding was observed with similar post-discharge drug therapy in the two groups. 
To this regard, it should be considered that the whole study population was made of patients 
undergoing percutaneous coronary intervention during the index admission, a feature that has 
selected a subset of NSTEACS patients suitable for percutaneous coronary intervention procedures. 
A significant and quantitatively remarkable reduction in cardiovascular events, including mortality, 
was observed among elderly NSTEACS patients treated invasively (mostly with percutaneous 
coronary intervention) both in observational registries9 and in randomized trials10-13. The low 
mortality rate observed in the whole study, and particularly among NSTEACS patients, may well 
reflect current mortality rates among elderly ACS patients treated by percutaneous coronary 
intervention, and has been observed in similar contemporary trials14 and registries15. Therefore, 
whereas the paradigm of NSTEACS patients having worse baseline characteristics is confirmed by 
our study in current practice in the elderly population, mortality seems to be lower now, as 
compared to elderly STEMI patients treated with primary percutaneous coronary intervention. 
As compared to STEMI patients, those with NSTEACS had a higher rate of re-infarction at one 
year, a ratio that has not changed compared to twenty years ago5, though the absolute rates have 
been dramatically reduced in both groups. This finding can be explained by the more severe 
coronary disease in NSTEACS patients. On the other hand, stroke rate was significantly higher in 
the STEMI group, maybe due to embolism from the infarcted left ventricle, or a higher rate of post-
myocardial infarction atrial fibrillation associated with left ventricular dysfunction. These two 
aspects require specific investigation.  Bleeding events were significantly higher among NSTEACS 
patients, a further proof of the greater frailty of these patients. 
The characteristic of the present study, based on a population enrolled in a randomized clinical trial, 
limits the applicability of our findings to patients treated by percutaneous coronary intervention 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 MA
NU
SC
RIP
T
 
 
early during index admission. However, the study exclusion criteria were limited to patients with 
recent severe bleeding and those with an indication to anticoagulant therapy, including atrial 
fibrillation. These clinical conditions, more prevalent among NSTEACS patients16, are associated 
with worse outcomes across the ACS spectrum. We did not carry corelab quantification of the 
echocardiography-measured left ventricular ejection fraction values, which were based on the 
individual investigator assessment as in clinical practice. Similarly, we did not collect blood 
samples to perform corelab measurements of cardiac troponin levels, and the many different 
analytical methods in use in the 32 participating Centers preclude a uniform estimate of the amount 
of myocardial damage. However, the lower ejection fraction and higher amount of myocardial 
damage in STEMI, as compared to NSTEACS, is a consolidated data even in the current era of 
universal invasive approach to ACS17,18.  The larger acute myocardial damage and decreased 
residual left ventricular dysfunction in STEMI patients are most likely to have significantly affected 
patient’s outcome.  
Strengths 
A major strength of this study is the comparable recruitment and setting of STEMI and NSTEACS 
patients, all derived from the same clinical trial and hence undergoing standardized procedures and 
follow-up by the same group of physicians.  In addition, we used a competing risk analysis to 
evaluate, beyond overall mortality, specific outcomes, including reinfarction, stroke and 
cardiovascular death. These results could provide new insights on the prognostic role of the 
different pathogenetic mechanisms involved in the two types of ACS and, perhaps, on a different 
therapeutic aggressiveness in STEMI vs NSTEACS patients. 
Conclusions 
In a contemporary cohort of elderly and very elderly patients admitted to hospital for an ACS and 
treated with early revascularization, ST elevation as presenting ECG is associated with worse 
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outcome, as compared to non-ST elevation, for at least one year of follow-up. Most of this 
difference accrues during the first 30 days, whereas little difference is observed thereafter. As 
shown by the Duke University Medical Center (Durham, NC) cohort of myocardial infarction 
patients undergoing coronary angiography and found to have at least one diseased coronary artery19 
(but with only two thirds of the NSTEMI patients undergoing revascularization) longer follow-up 
may be needed to observe worse clinical outcome in NSTEACS, consistent with the overall worse 
clinical characteristics and longer cardiac disease history of this population.  
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Figure legends 
Figure 1. One-year crude cumulative incidence (CCI) of study outcomes according to presenting 
ECG. CV: cardiovascular; NSTEACS: Non ST Elevation Acute Coronary Syndrome; STEMI: ST 
Elevation Myocardial infarction; MI: Myocardial Infarction 
 
 
 
Table 1: Baseline clinical characteristics 
 STEMI 
(n=595) 
NSTEACS 
(n=848) 
p value 
Age (median, IQR) 80 (77-84)             80 (77-83) 0.232 
Sex  
                 Female  264 (44.4) 312 (36.8) 0.004 
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                     Male 331 (55.6) 536 (63.2)  
Body-mass index (kg/m2)  25.4 (23.5-27.8)        25.8 (23.5-28.3) 0.125 
Medical history  
     Family history of cardiovascular disease                   88 (14.8) 127 (15.0) 0.995 
     Diabetes 151 (25.4) 269 (31.7) 0.009 
     Hypertension 426 (71.6) 694 (81.8) <0.001 
     Hypercholesterolemia 228 (38.3) 416 (49.1) <0.001 
     Current smoker 63 (10.6) 68 (8.0) 0.094 
     Chronic respiratory failure 23 (3.9) 64 (7.5) 0.004 
     Liver disease  10 (1.7) 14 (1.6) 0.965 
eGFRa at admission (ml/min) 55 (43-67) 55 (42-68) 0.781 
Hemoglobin at admission (g/dL)  
                   males  14.0 (1.4) 13.6 (1.5) < 0.001 
                   females 12.8 (1.4) 12.6 (1.4) 0.091 
Neurological disorders 18 (3.0) 28 (3.3) 0.768 
Malignancies 23 (3.9) 22 (2.6) 0.171 
Previous cardiovascular events  
        Myocardial infarction 52 (8.7) 222 (26.2) <0.001 
        Percutaneous coronary interventions 62 (10.4) 202 (23.8) <0.001 
        Coronary artery bypass grafting 22 (3.7) 106 (12.5) <0.001 
       Peripheral vascular disease 36 (6.1) 89 (10.5) 0.003 
       Atrial fibrillation 16 (2.7) 40 (4.7) 0.050 
Ongoing cardiovascular medicationsb  
   Aspirin 208 (47.1) 508 (67.8) <0.001 
   Clopidogrel  39 (8.8) 175 (23.4) <0.001 
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   Betablockers  152 (34.4) 342 (45.7) <0.001 
   Calcium antagonists  147 (33.1) 202 (27.0) 0.026 
   ACE-inhibitors/ARBs  290 (65.7) 500 (66.7) 0.075 
   Diuretics  125 (28.3) 297 (39.6) <0.001 
   Nitrates 34 (7.7) 177 (23.6) <0.001 
   Statins 135 (30.5) 394 (52.6) <0.001 
Data are n (%) for categorical variables and median (IQR) for continuous variables. 
STEMI=ST-segment elevation myocardial infarction. NSTEACS=non-ST elevation acute coronary 
syndrome. ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor antagonist. 
 aestimated Glomerular Filtration Rate by the Cockroft-Gault formula. 
 bData available on 1191 patients (442 STEMI and 749 NSTEACS), where percentages were calculated on 
available data. 
 
 
Table 2: Characteristics of index ACS event 
 STEMI 
(n=595) 
NSTEACS 
(n=848) 
p Value 
Left ventricular ejection fraction 45 (40-55) 50 (45-55) <0.001 
Coronary angiography   
       Radial access  457 (76.8) 652 (76.9) 0.702 
Number of vessels with critical stenosisa   <0.001 
       One-vessel disease 263 (44.4) 314 (37.1)  
       Two-vessel disease  183 (30.9) 240 (28.4)  
       Three-vessel disease or greater 141 (23.8) 291 (34.4)  
 Left main 16 (2.7) 83 (9.8) <0.001 
 PCI performed  587 (98.7) 846 (99.8) 0.012 
 Procedural treatmentb   0.032 
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      Stentingb 539 (96.4) 787 (94.2) 0.085 
              Drug eluting stents implanted 354 (65.7) 590 (75.0)  
              Bare metal stents implanted 131 (24.3) 124 (15.8)  
              Other (unknown type) 54 (10.0) 73 (9.2)  
      Drug Eluting Balloons  4 (0.70) 22 (2.7)  
      Plain balloon angioplasty 16 (2.9) 26 (3.1)  
Procedural success 
Length of hospital stay (days) 
569 (95.6) 
6 (5-9) 
818 (96.5) 
6 (4-8) 
0.891 
<0.01 
Data are n (%) for categorical variables and median (IQR) for continuous variables. 
STEMI=ST-segment elevation myocardial infarction. NSTEACS=non-ST elevation acute coronary 
syndrome.  
aData available on 1438 patients (592 STEMI and 846 NSTEACS), where percentages were calculated on 
available data.  
bData available on 1384 patients (556 STEMI and 828 NSTEACS), where percentages were calculated on 
available data.  
 
Table 3: Drug therapy during admission and at discharge  
 STEMI 
(n=595) 
NSTEACS 
(n=848) 
p Value 
Peri-procedural medicationsa    
Aspirin 550 (93.2) 813 (97.1) 0.001 
Glycoprotein IIb/IIIa antagonists 154 (26.1) 81 (9.7) <0.001 
Unfractionated heparin 520 (88.1) 626 (74.8) <0.001 
Low molecular weight heparin 35 (5.9) 241 (28.8) <0.001 
Bivalirudin  88 (14.9) 36 (4.3) <0.001 
Medications at dischargeb  
       Aspirin  569 (98.8) 830 (99.3) 0.329 
       Proton Pump Inhibitors  551 (95.7) 756 (90.4) <0.001 
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       Betablockers  444 (77.1) 661 (79.1) 0.375 
       Calcium antagonists 70 (12.1) 225 (26.9) <0.001 
       ACE-inhibitors or ARBs 484 (83.3) 689 (81.4) 0.365 
       Diuretics  224 (38.9) 335 (40.1) 0.655 
       Nitrates 57 (9.9) 126 (15.1) 0.004 
       Statins   554 (96.2) 790 (94.5) 0.147 
       Oral anticoagulant 20 (3.5) 17 (2.0) 0.096 
Data are n (%). ACE=angiotensin-converting enzyme.  
STEMI=ST-segment elevation myocardial infarction. NSTEACS=non-ST elevation acute coronary 
syndrome. ARB=angiotensin-receptor antagonist. 
aData available on 1427 patients (590 STEMI and 837 NSTEACS), where percentages were calculated on 
available data. bData available on 1412 patients (576 STEMI and 836 NSTEACS), where percentages were 
calculated on available data. 
 
Table 4. Thirty-day and one-year crude cumulative incidence (CCI) and 95% 
confidence intervals (CIs) of study outcomes according to presenting ECG 
Study outcome Group 
30-day events 
(n, %) 
CCI at 30 days 
(% of patients) 
(95% CI) 
1-year 
events 
(n, %) 
CCI at 1 year 
(% of patients) 
(95% CI) 
Cardiovascular death STEMI  20 (3.4) 3.38 (3.24-3.53) 26 (4.4) 4.43 (4.26-4.60) 
 NSTEACS  12 (1.4) 1.43 (1.35-1.51) 22(2.6) 2.98 (2.85-3.11) 
Non-Cardiovascular death STEMI  5 (0.8) 0.85 (0.78-0.93) 18 (3.0) 3.63 (3.45-3.80) 
 NSTEACS 2 (0.2) 0.24 (0.21-0.27) 13 (1.5) 1.73 (1.64-1.83) 
Myocardial infarction              STEMI  4 (0.7) 0.68 (0.61-0.74)   7 (1.2) 1.25 (1.16-1.35)   
 NSTEACS  5 (=.6) 0.59 (0.54-0.64)      31 (3.7) 4.46 (4.30-4.62)   
Stroke   STEMI  5 (0.8) 0.85 (0.77-0.92)   15 (2.5) 3.34 (3.16-3.51)   
 NSTEACS       0 0          5 (0.6) 1.19 (1.09-1.30)   
STEMI=ST-segment elevation myocardial infarction. NSTEACS=non-ST elevation acute coronary 
syndrome. CCI: Crude Cumulative Incidence 
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Table 5. Estimated rates (per person-year) with lower/upper bounds of 95% confidence 
intervals (CIs) and cause-specific hazard ratios (HRs) with corresponding 95% CIs. 
First event Estimated 
rates (95% CI) 
0-30 days   
p 
value 
Estimated 
rates (95% 
CI) 
31-365 days   
p 
value 
HRac 
(95%CI) 
HRbc 
(95%CI) 
Cardiovascular death           
STEMI 
           NSTEACS 
                                  
0.428 (0.276-
0.664)       0.177 
(0.100-0.312) 
 
0.016 
                                  
0.012 (0.005-
0.027)       0.014 
(0.007-0.261) 
 
0.805 
1.70 (0.97-3.01) 
 
1.85 (1.02-
3.36) 
 
 Non-Cardiovascular 
death 
          STEMI 
          NSTEACS 
 
                                  
0.107 (0.044-
0.257)       0.029 
(0.007-0.118) 
 
0.124 
                                  
0.026 (0.015-
0.046)       0.015 
(0.008-0.028) 
 
0.179 
2.01 (0.99-4.11) 
 
2.10 (1.01-
4.38) 
 
Myocardial Infarction 
          STEMI 
          NSTEACS 
 
                                  
0.085 (0.032-
0.228)       0.074 
(0.030-0.177) 
 
0.826 
                                  
0.006 (0.002-
0.020)       0.036 
(0.025-0.053) 
 
0.004 
0.33 (0.14-0.74) 
 
0.44 (0.19-
1.03) 
 
Stroke                                
STEMI                            
NSTEACS                                        
 
                                 
0.107 (0.044-
0.257)       not 
estimable 
 
na 
                                  
0.020 (0.011-
0.038)       0.007 
(0.003-0.017) 
 
0.049 
    4.25 (1.55-
11.7) 
4.80 (1.68-
13.7) 
STEMI=ST-segment elevation myocardial infarction. NSTEACS=non-ST elevation acute coronary syndrome. 
a estimated from cause specific regression analysis for patients with STEMI compared to NSTEACS. 
b further adjusted for age classes, gender, previous myocardial infarction.  
C estimated over 365-day follow up 
 
